Preclinical biodistribution and dosimetry and human biodistribution comparing ¹⁸F-rhPSMA-7 and single isomer ¹⁸F-rhPSMA-7.3.

ABSTRACT:

Background

Radiohybrid prostate-specific membrane antigen (rhPSMA) ligands such as ¹⁸F-rhPSMA-7 are a new class of theranostic agents in clinical development for prostate cancer. We compared preclinical dosimetry and human biodistribution of ¹⁸F-rhPSMA-7 with that of single diastereoisomer form, ¹⁸F-rhPSMA-7.3.

Methods

Preclinical dosimetry was performed with SCID-mice sacrificed at multiple timepoints (10-300 min) post-injection of 25.6 ± 3.6 MBq ¹⁸F-rhPSMA-7 or 28.5 ± 4.8 MBq ¹⁸F-rhPSMA-7.3 (n = 3-6 mice per timepoint). Heart, lung, liver, spleen, pancreas, fat, stomach, small intestine, large intestine, kidney, muscle, bone, bladder, testicles, tail, and brain tissue were harvested, and urine and blood samples collect

SUBMITTER: Knorr K 

PROVIDER: S-EPMC8816989 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature